The Quantellect read.As of Nov 19, 2026, 3 active firms cover Insight Molecular Diagnostics Inc: 3 rate it Buy or better, 0 sit at Neutral, and 0 rate it Sell or worse, a buy consensus. Targets span $8.00 to $12.00, a moderate spread. The average target of $9.67 sits 516% above the current $1.57. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-0.22 next quarter toward $-0.80 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 active firms
Buy
Strong Buy00%
Buy3100%
Neutral00%
Sell00%
Strong Sell00%
Based on 3 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$9.67
+515.7% upside
Average target across 3 active firms as of Nov 19, 2026 vs $1.57 current
Highest Target$12.00
Average Target$9.67
Lowest Target$8.00
Detailed analyst forecasts for IMDX
Showing 1–3 of 3 named analysts shown · 3 active firms in the rating projection
As of Nov 19, 2026, 3 of 3 active firms rate IMDX a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
IMDX EPS & revenue forecast
EPS · NEXT QUARTER
$-0.22
Range $-0.22 – $-0.22 · 2 analysts
Next period, 2 analysts expect Insight Molecular Diagnostics Inc. to earn $-0.22 a share (range $-0.22 – $-0.22), versus — a year earlier. Full-year consensus is $-0.93, growing to $-0.80 the year after.
REVENUE · NEXT QUARTER
$300.9K
Range $200.0K – $450.0K · 2 analysts · +840% YoY
Revenue is expected to reach $300.9K (range $200.0K – $450.0K), +840.4% year-over-year. Full-year consensus is $966.2K, rising to $6.7M next year.
Top analysts covering Insight Molecular Diagnostics Inc.
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on IMDX.
#1
Mark Massaro
BTIG · Rank #220
Neutral
No targeton IMDX
Overall win rate
44%
+ Follow
#2
Mike Matson
Needham · Rank #285
Buy
$9.00+473.2% to target
Overall win rate
36%
+ Follow
#3
TF
Thomas Flaten
Lake Street · Rank #306
Buy
$12.00+664.3% to target
Overall win rate
40%
+ Follow
IMDX stock forecast FAQ
What is IMDX's average 12-month price target?+
The 3 active firms with a live target average $9.67 for Insight Molecular Diagnostics Inc. over the next 12 months, ranging from a $12.00 high to a $8.00 low, as of Nov 19, 2026.
Is IMDX stock a Buy, Sell or Neutral right now?+
The current consensus is Buy. Of the 3 active firms as of Nov 19, 2026, 3 rate it Buy or Strong Buy, 0 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for IMDX?+
The Street-high target is $12.00 (Lake Street), and the Street-low is $8.00 (LUCID CAPITAL MARKETS). The average of all 3 active-firm targets is $9.67.
How many active Wall Street firms cover IMDX?+
3 active firms have a recognized rating on Insight Molecular Diagnostics Inc. as of Nov 19, 2026, and 3 active firms carry a live 12-month price target.
Who is the most accurate analyst covering IMDX?+
Among analysts who currently cover IMDX, Mark Massaro of BTIG has the strongest overall Quantellect track record (Rank #220). Their current call is Neutral.
What is Insight Molecular Diagnostics Inc.'s projected EPS for next quarter?+
The consensus estimate is $-0.22 per share (range $-0.22 – $-0.22) across 2 analysts. Full-year EPS is projected at $-0.93, rising to $-0.80 the following year.
How much revenue is Insight Molecular Diagnostics Inc. expected to report next quarter?+
Consensus revenue is $300.9K (range $200.0K – $450.0K). Full-year revenue is projected at $966.2K, growing to $6.7M next year.
Have analysts been upgrading or downgrading IMDX lately?+
As of Nov 19, 2026, 3 of 3 active firms rate IMDX a Buy (0 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their IMDX calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.